

OFFICIAL

PATENTS

Attorney Docket No. 25352-0029


RECEIVED

CENTRAL FAX CENTER

DEC 17 2003

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being transmitted by facsimile to the US PTO at fax number 703-872-9306 on December 17, 2003.


Sam L. Nguyen, Reg. No. 52,496

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Prasad V.V.S.V. Mancham et al : Confirmation No. 1824

App. No.: 09/977,059 : Art Unit: 1617

Filed: October 11, 2001 : Examiner: Mojdeh Bahar

For: Insulin Receptor Activators for the Treatment of Metabolic Disorders Induced by Treatment with HIV Protease Inhibitors

Mail Stop RCE

Commissioner for Patents

PO Box 1450

Alexandria VA 22313-1450

Sir:


REQUEST FOR CONTINUED EXAMINATION

This is a request for continued examination under 37 CFR 1.114 of the above application.

The submission required under 37 CFR 1.114 is enclosed herewith, totaling, with this Request, 12 pages.

The fees of \$2,890.00 (RCE fee of \$770.00, and the fee for three months' extension of the period for response to the Office Action of June 18, 2003, of \$2,010.00, and the terminal disclaimer fee of \$110.00), and any additional fees that may be required, are authorized to be charged to Deposit Account No. 08-1641 referencing attorney docket no. 25352-0029.

Respectfully submitted,




Sam L. Nguyen
Attorney for Applicant
Reg. No. 52,496

Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7028
December 17, 2003

SV 473189 v1
12/17/03 2:30 PM (25352.0029)

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being transmitted by facsimile to the US PTO at fax number 703-872-9306 on December 17, 2003.


Sam L. Nguyen, Reg. No. 92,496

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Prasad V.V.S.V. Mancham et al : Confirmation No. 1824

App. No.: 09/977,059 : Art Unit: 1617

Filed: October 11, 2001 : Examiner: Mojdeh Bahar

For: Insulin Receptor Activators for the Treatment of Metabolic Disorders Induced by Treatment with HIV Protease Inhibitors

Mail Stop RCE

Commissioner for Patents

PO Box 1450

Alexandria VA 22313-1450

Sir:

SUBMISSION UNDER 37 CFR 1.114

In response to the Office Action mailed June 18, 2003, which Office Action was made final, and for which a three months' extension of time is requested and the fee authorized in the accompanying Request for Continued Examination, please enter the following amendment and consider the following remarks.

AMENDMENT

In the Specification:

Amend the paragraph of the specification at page 3, lines 21-29 to read as follows:

In particular, compounds of Formulas I-VII are useful for the treatment of metabolic diseases induced by treatment with an HIV protease inhibitor, and for the treatment of HIV protease inhibitor-induced insulin resistance, hyperglycemia, diabetes, ketoacidosis, lipodystrophy and hypertriglyceridemia in humans. The methods of the invention also

include the co-administration of insulin in conjunction with the administration of receptor-activating compounds for such treatment. Compounds of Formula I-IV are also disclosed as being useful in treating diabetes in US Patent Applications Nos. 09/872,763 (now US Patent No. 6,479,548) (and Provisional Application No. 60/208,591), 09/949,165 (now US Patent No. 6,600,069) (and Provisional Application No. 60/230,738), and 09/579,279 (now US Patent No. 6,458,998), and PCT/US00/14644, incorporated herein by reference.

In the Claims:

Cancel all present claims (which are claims 1-20).

Add new claims 21-36 as noted on the following pages.